Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Oxybutinyn Vaginal Ring
DR-3001 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | PLACEBO_COMPARATOR | - |
| Oxybutinyn Vaginal Ring 4mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Oxybutinyn Vaginal Ring 6mg | EXPERIMENTAL | inserted daily and replaced every 4 weeks |
| Name | Type | Description |
|---|---|---|
| DR-3001 | DRUG | 4mg/day vaginal ring inserted vaginally and replaced every 4 weeks |
| Placebo | DRUG | Placebo vaginal ring inserted vaginally and replaced every 4 weeks |
| Oxybutinyn Vaginal Ring 4mg | DRUG | - |
| Oxybutinyn Vaginal Ring 6mg | DRUG | - |
Inclusion Criteria: * Women 18 years of age or older, ambulatory, with a history and presentation consistent with urge incontinence ≥ 6 months * Able to distinguish between stress and urge incontinence * During the Screening Period able to demonstrate the presence of overactive bladder with urge in...
DR-3001 is an investigational small molecule being developed for the treatment of overactive bladder. It is intended for use in women with this condition. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
DR-3001 is being developed by Teva Pharmaceutical Industries Limited, a company traded on the stock exchange under the ticker symbol TEVA. The drug is currently in Phase 3 clinical trials for overactive bladder.
DR-3001 is in Phase 3 clinical development. It is an investigational drug for overactive bladder and has not been approved by regulatory agencies. One Phase 3 trial has been completed, involving 1,104 female participants.
DR-3001 has one completed Phase 3 clinical trial, identified as NCT00685113. This trial evaluated the efficacy and safety of DR-3001 in women with overactive bladder. The study was randomized, double-blind, and placebo-controlled, enrolling 1,104 participants in the United States and Canada.
DR-3001 is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for overactive bladder. A Phase 3 trial has been completed, but the drug has not yet received regulatory approval.